Nebenwirkungen · Yuflyma
Yuflyma 80 mg solution for injection in pre-filled syringe Yuflyma 80 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 77
HOS-145102 · Präparat HOS-099300
* further information is found elsewhere in sections 4.3, 4.4 and 4.8 ** including open label extension studies 1) including spontaneous reporting data 2) The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months. Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of approximately 1-2 years without control group, particularly in patients with Crohn’s disease and ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the anti-inflammatory effect of adalimumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-25T13:01:00Z · SHA-256 0529a5530a0ac161111f0aae5e79ac0bf7e7b8f3619b8a75f76749820992ed11 · Passage 2c2cd22f294b5ad64e3a0e20cf46a7def6c8c0d03fd5ec53983fac2d50e2dfa8 · Zeichen 14876–15583 im Abschnitt